CN101610759A - 由跨膜肽组成的自组装纳米颗粒及其用于特异性肿瘤内递送抗癌药物的应用 - Google Patents

由跨膜肽组成的自组装纳米颗粒及其用于特异性肿瘤内递送抗癌药物的应用 Download PDF

Info

Publication number
CN101610759A
CN101610759A CNA2007800459379A CN200780045937A CN101610759A CN 101610759 A CN101610759 A CN 101610759A CN A2007800459379 A CNA2007800459379 A CN A2007800459379A CN 200780045937 A CN200780045937 A CN 200780045937A CN 101610759 A CN101610759 A CN 101610759A
Authority
CN
China
Prior art keywords
peptide
nanoparticles
hydrophobic agents
nano
particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800459379A
Other languages
English (en)
Chinese (zh)
Inventor
娜佳·I·塔拉索夫
谢尔盖·G·塔拉索夫
克里斯托弗·J·米海达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of CN101610759A publication Critical patent/CN101610759A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNA2007800459379A 2006-11-07 2007-11-06 由跨膜肽组成的自组装纳米颗粒及其用于特异性肿瘤内递送抗癌药物的应用 Pending CN101610759A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86466506P 2006-11-07 2006-11-07
US60/864,665 2006-11-07

Publications (1)

Publication Number Publication Date
CN101610759A true CN101610759A (zh) 2009-12-23

Family

ID=39365311

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800459379A Pending CN101610759A (zh) 2006-11-07 2007-11-06 由跨膜肽组成的自组装纳米颗粒及其用于特异性肿瘤内递送抗癌药物的应用

Country Status (9)

Country Link
US (1) US9326950B2 (enExample)
EP (1) EP2086521A2 (enExample)
JP (1) JP2010509241A (enExample)
CN (1) CN101610759A (enExample)
AU (1) AU2007316416A1 (enExample)
CA (1) CA2668638A1 (enExample)
NZ (1) NZ576769A (enExample)
WO (1) WO2008058125A2 (enExample)
ZA (1) ZA200903125B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602856A (zh) * 2015-12-18 2018-09-28 康斯乔最高科学研究公司 一种包括低聚甘氨酸自组装体和纳米线的材料

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101610759A (zh) * 2006-11-07 2009-12-23 美国政府卫生与公共服务部 由跨膜肽组成的自组装纳米颗粒及其用于特异性肿瘤内递送抗癌药物的应用
WO2012162628A2 (en) 2011-05-25 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipopeptide inhibitors of ras oncoproteins
US9180203B2 (en) 2012-10-23 2015-11-10 The Johns Hopkins University Self-assembling drug amphiphiles and methods for synthesis and use
WO2017173398A1 (en) 2016-04-01 2017-10-05 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
WO2019018572A1 (en) * 2017-07-18 2019-01-24 Duke University COMPOSITIONS AND METHODS COMPRISING SELF-ASSEMBLY PEPTIDE-POLYMER NANOFIBERS FOR SUBLINGUAL IMMUNIZATION
WO2026018050A1 (en) 2024-07-14 2026-01-22 Zare Zardini Hadi Pistacia-derived bioactive peptides encapsulated in soy protein nanoparticles as an anticancer drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT892801E (pt) 1996-04-12 2002-06-28 Us Gov Health & Human Serv Compostos derivados de acridona uteis como agentes antineoplasicos e antiretrovirais
US7105488B1 (en) 1998-02-27 2006-09-12 The United States Of America As Represented By The Department Of Health And Human Services G protein-coupled receptor antagonists
CA2321962C (en) 1998-02-27 2014-07-15 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services G protein-coupled receptor antagonists
US7517849B1 (en) * 1999-11-18 2009-04-14 The United States Of America As Represented By The Secretary Of Health And Human Services Inhibition of ABC transporters by transmembrane domain analogs
AU2001240054B2 (en) 2000-03-07 2005-08-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 1,8-Naphthalimide Imidazo[4,5,1-de]acridones with Anti-Tumor Activity
CN1981873A (zh) * 2000-06-09 2007-06-20 莱古伦公司 制备微胶粒的方法和所述微胶粒的用途
WO2002062823A2 (en) * 2001-02-02 2002-08-15 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules
WO2006010083A2 (en) * 2004-07-08 2006-01-26 Molecular Therapeutics, Inc. Biodegradable nanoparticles
CN101610759A (zh) * 2006-11-07 2009-12-23 美国政府卫生与公共服务部 由跨膜肽组成的自组装纳米颗粒及其用于特异性肿瘤内递送抗癌药物的应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602856A (zh) * 2015-12-18 2018-09-28 康斯乔最高科学研究公司 一种包括低聚甘氨酸自组装体和纳米线的材料

Also Published As

Publication number Publication date
JP2010509241A (ja) 2010-03-25
ZA200903125B (en) 2010-05-26
NZ576769A (en) 2012-01-12
WO2008058125A3 (en) 2008-10-16
CA2668638A1 (en) 2008-05-15
AU2007316416A1 (en) 2008-05-15
EP2086521A2 (en) 2009-08-12
US20100034896A1 (en) 2010-02-11
WO2008058125A2 (en) 2008-05-15
US9326950B2 (en) 2016-05-03

Similar Documents

Publication Publication Date Title
AU2021200135B2 (en) Liposome compositions and methods of use thereof
Saad et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?
Xu et al. Smart and hyper-fast responsive polyprodrug nanoplatform for targeted cancer therapy
Accardo et al. Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs
M. Leite et al. Peptide self-assemblies for drug delivery
Wang et al. Zwitterionic Janus Dendrimer with distinct functional disparity for enhanced protein delivery
US9326950B2 (en) Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs
WO2017059786A1 (zh) 一种肿瘤靶向的新型多肽
EP3405429B1 (en) Formation of functionalized nanoparticles by supramolecular co-assembly
Stefanick et al. Improved peptide-targeted liposome design through optimized peptide hydrophilicity, ethylene glycol linker length, and peptide density
CN110114367B (zh) Vap多肽及其在制备靶向诊疗肿瘤药物中的应用
Ruan et al. Stapled RAP12 peptide ligand of LRP1 for micelles-based multifunctional glioma-targeted drug delivery
CN105476975B (zh) 主动靶向型抗脑肿瘤药物及其制备方法
EP2789348B1 (en) Liposomes and corresponding production method
CN103656650B (zh) 一种pH敏感的脑部肿瘤双级靶向纳米递药系统及制备方法和应用
WO2017063542A1 (zh) 稳定化a7r多肽及其在构建肿瘤靶向诊治递药系统中的用途
Ashwanikumar et al. Supramolecular self assembly of nanodrill-like structures for intracellular delivery
Wang et al. One-step self-assembling method to prepare dual-functional transferrin nanoparticles for antitumor drug delivery
CN106565825A (zh) 稳定化a7r多肽及其在构建肿瘤靶向诊治递药系统中的用途
WO2018049155A1 (en) Compositions comprising polymeric nanoparticles and mcl-1 antagonists
US20190290726A1 (en) Protein polymer fusions for subcutaneous delivery of small molecules
Tong et al. A Small Peptide Increases Drug Delivery in Human Melanoma Cells. Pharmaceutics 2022, 14, 1036
Tesauro et al. Peptide-Based Drug Delivery Systems: Future Challenges, Perspectives, and Opportunities in Nanomedicine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20091223

C20 Patent right or utility model deemed to be abandoned or is abandoned